See the issue highlights and editor picks for the June issue of JDD!
JDD Special Focus on Acne and Rosacea’s Guest Editor, Dr. James Q. Del Rosso, emphasizesthe importance of selecting treatment that targets the specific clinical manifestations of rosacea in his Editorial, What Is “PFE”? It May Just Be Time You Found Out….
The Use of Oral Antibiotics in the Management of Rosacea provides a complete review of the use of oral antibiotics for the treatment of rosacea.
Adapalene 0.3%-Benzoyl peroxide 2.5% gel used in the treatment of moderate or severe facial acne is effective and well tolerated in patients from Asian, African-American, and Latin-American ethnicities in Patient-Reported Outcomes in Acne Patients With Skin of Color Using Adapalene 0.3%-Benzoyl Peroxide 2.5%: A Prospective Real-World Study.
Results demonstrated that a single, high-density MFU-V treatment may be effective for treating erythematotelangiectatic rosacea in Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea.
Minimizing risk of vascular complications through a comprehensive understanding of vascular anatomy and careful technique is important in Arterial Occlusion and Necrosis Following Hyaluronic Acid Injection and a Review of the Literature.
Update on the Treatment of Scars reviews the many options available for the treatment of different types of scars and insight on how to better choose light and energy devices based on the type of scarring the patient presents.
Clascoterone topical cream 1% is a novel androgen receptor inhibitor, the first of its kind, that has shown efficacy in IGA success and reduction of acne lesions in males and females and is well-tolerated with no clinically relevant safety issues noted in A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Facial Acne Vulgaris: An Open-Label Phase 2a Study supports the safety and tolerability profile including limited systemic exposure and mostly mild local skin reactions.
Botanical combination is the key factor for efficacy and improvement of AD symptoms in Validation of Botanical Treatment Efficiency for Adults and Children Suffering from Mild to Moderate Atopic Dermatitis.
Connecting the Dots: From Skin Barrier Dysfunction to Allergic Sensitization, and the Role of Moisturizers in Repairing the Skin Barrier provides an update on how dysfunction at each level of the skin barrier can lead to allergic sensitization, atopic march, and contact dermatitis, and examines how to best repair and maintain this barrier through the use of moisturizers.
Different injection volumes necessary to deliver aesthetically appealing results when utilizing the subdermal vs the supraperiosteal technique can be explained by the region-specific surface volume coefficient in Clinical Validation of the Surface Volume Coefficient for Minimally Invasive Treatment of the Temple.
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris compares efficacy, safety, and tolerability of a novel formulation that could extend the treatment, especially in patients susceptible to skin irritation.
DNA Repair Enzyme Containing Lip Balm for the Treatment of Actinic Cheilitis: A Pilot Study offers a less aggressive option for treating actinic cheilitis.
